A prospective, open-labelled, randomized, multicenter phase II study to evaluate efficacy and safety of Erlotinib vs NP chemotherapy as adjuvant therapy in post radical operation NSCLC patients with EGFR19 or 21 exon mutation
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2016
At a glance
- Drugs Erlotinib (Primary) ; Cisplatin; Vinorelbine
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 19 Oct 2016 Planned End Date changed from 1 Mar 2019 to 1 Oct 2020.
- 19 Oct 2016 Planned primary completion date changed from 1 Mar 2019 to 1 Oct 2020.
- 30 Jul 2014 Status changed to completed as reported by Chinese Clinical Trial Register.